¡i¦æ¹M¤Ñ¤U®È¹C¹q¤l³ø¡j¨C¤ë¥ø¹ººëªöªº®È¹C±MÃD¡AÅý§A·P¨ü¬ü´º»P¦h¼Ë­·±¡¡A³Ð³yÄÝ©ó­Ó¤Hªº®È¹C­õ¾Ç¡C ½Ö¯àÀ°§AÁÚ¦V°·±d¤H¥Í¡H¶g¶g´£¨Ñ³Ì·sªº°·±d±¡¸ê¡A¡i±`¬KEVERGREEN¡jÀ°§Aªº°·±d¥´©³¡A¤H¥Í¥[¤À¡I
¡¹ µLªk¥¿±`ÂsÄý¤º®e¡A½Ð«ö³o¸Ì½u¤W¾\Ū
·s»D  °·±d  udn³¡¸¨®æ  
2023/08/03 ²Ä507´Á  |  ­q¾\¡þ°h­q  |  ¬Ý¾ú¥v³ø¥÷  |  ¥_¬ü´¼Åvºô¯¸
 
 
 
 
±M§QµûªR Åöíw¯gÃĪ«¤Æ¾Çºc³yªºÅã¦Ó©ö¨£©Ê¡GPfizer Inc. v. Teva Pharmaceuticals USA, Inc.(Fed. Cir. 2014)
   
ªk³W¶D³^ USPTO¸Õ¦æ¥HEmail±Hµo¦~¶O¤íú¬ÛÃö©x¨ç
   
²`¤J³ø¾É Àb«È§ðÀ»¦A½·s¡G¥ø·~¤£¥i¤£ª¾ªº¸ê¦w§ðÀ»¤âªk
   
¬ãµo³Ð·s 2035¦~¥þ²y¹q°Ê¨®¤ñ­«±N¹F¤E¦¨¡A¬ü¾¥¦¨¬°¼öªù§ë¸ê¦aÂI
   
´¼°]ºÞ²z ¬ü°ê³Ì°ªªk°|¬°°Ó¼Ð«IÅv¹Ò¥~®Ä¤O¹º¬É½u¡G2023¦~Abitron Austria GmbH v. Hetronic Int'l, Inc.®×
   
 
Åöíw¯gÃĪ«¤Æ¾Çºc³yªºÅã¦Ó©ö¨£©Ê¡GPfizer Inc. v. Teva Pharmaceuticals USA, Inc.(Fed. Cir. 2014)
³¢§ÊÀÚ¢¬±M§Q®v

ÂåÃĬO³\¦h¤H¤é±`©Ò¥²¶·¨Ï¥Î¨ìªº¡A¨Ò¦p¡G¦³µÛÅöíw¯gªº±wªÌ¡A³£»Ý­n©w®ÉªA¥ÎªvÀøÃĪ«¡A¦ý¬O¸û¤Ö¦³¤H·|·Qª¾¹D¦Û¤v¨Ï¥ÎÂåÃĪº¦¨¤À¬°¦ó¡A§ó¤£¥Î»¡¶i¤@¨B¤F¸Ñ¨ä¤¤ªº¤Æ¾Çºc³y¡CµM¦Ó¡AÂåÃĪº¤Æ¾Çºc³y¬O¯f¯gÀø®Äªº¨Ó·½¡A¤]¦h¥b¬O±M§QÅv©Ò¼h¼h«OÅ@ªº³¡¤À¡A¦Ó¥B§ó¬OÂåÃıM§Q«IÅv¶D³^¤¤±`³Q«I®`ªº¼öÂI¤§¤@¡C¥Ñ¦¹¥iª¾¡AÂåÃĤƾǺc³y¦³¤@©wµ{«×ªº­«­n©Ê¡C

¨ä¤¤¡AÅöíw¯gÃĪ«ªº¤Æ¾Çºc³y§óÂA¦³¤H±´°Q¡A¦]¦¹¡A¥»¤åÂÇ¥ÑÅöíw¯gÃĪ«¤Æ¾Çºc³yªºÅã¦Ó©ö¨£©Ê¡GPfizer Inc. v. Teva Pharmaceuticals USA, Inc. (Fed. Cir. 2014).®×¥ó[1]¨Ó±´°QÅöíw¯gÃĪ«¤Æ¾Çºc³yªºÅã¦Ó©ö¨£©Ê¡C

¥»®×­I´º

¥»®×³Q§i±è¥Ë (Teva) ¾Ç¦WÃļt¦]¬°¦V­¹«~ÃĪ«ºÞ²z§½ (FDA) ´£¥X¤FLyrica—û (¦¨¤À¬°´¶·ç¤ÚªL¡Apregabalin) ªº¾Ç¦WÃij\¥i¤§Â²©ö·sÃĤW¥«µ{§Ç (ANDA) ¡A­ì§i½÷·ç (Pfizer, Inc.) Ãļt©ó¬O¦V¬ü°ê¼w©Ô¥Ë¦{ (the District of Delaware) ªº¦a¤èªk°|´£¥X±M§Q«IÅv¶D³^¡A¥D±i³Q§i±è¥Ë¾Ç¦WÃļt«I®`¤F¨tª§±M§Qªº¥Ó½Ð±M§Q½d³ò¡A±è¥Ë¾Ç¦WÃļt«h¥D±i­ì§i½÷·çÃļtªº±M§QÃĪ«ºc³y¬°Åã¦Ó©ö¨£¡A¦a¤èªk°|¸g¹L§P¨M«á»{©w¨tª§±M§QÃĪ«ºc³y¤£¦]Åã¦Ó©ö¨£¦ÓµL®Ä¡C³Q§i±è¥Ë¾Ç¦WÃļt¤£ªA¦a¤èªk°|ªº§P¨M¡A©Ò¥H´£¥X¤W¶D¡C

Åöíw¯g»P¨äªvÀøÃĪ«

Åöíw¯g (epilepsy) ¡A¬O«ü¥Ñ¬Y¨Ç¯e¯f©Î¯fÅܳy¦¨¸£²Ó­M²§±`©Ê¡B°}µo©Êªº©ñ¹q¡A¨Ï±wªÌ²£¥Í¦UºØ¯gª¬»P¸£ªiÅܤơCÁ{§É¤W§e²{¤§¯gª¬ºÙ¬°¡uµo§@ (seizure) ¡v¡A¦h¦¸ªºµo§@«hºÙ¬°¡uÅöíw¯g¡v[2]¡C¥Ø«eÅöíw¯gªºÃĪ«¥D­n¬O¥H£^-®ò°ò¤B»Ä (£^-aminobutyric acid¡AGABA¡A¹Ï1) Ãþ©ÎÂ÷¤l³q¹DªýÂ_¾¯¬°¥D¡A«eªÌ¨Ò¦p¡G¥[¤Ú¼Q¤B (gabapentin) »P´¶·ç¤ÚªL¡A«áªÌ«h¨Ò¦p¡G©Ô¬ìñQÓi (lacosamide)¡B­f§´­^ (phenytoin) »P¥d°¨¦è¥­ (carbamazepine) µ¥[3]¡C

A«¬£^-Ói°ò¤B»Ä¨üÅé (gamma aminobutyric acid A receptor¡AGABAA receptor¡A¹Ï2) ¬°¤@ºØ´âÂ÷¤l(chloride ion) ³q¹D«¬ªº¨üÅé¡A¨ä¥Ñ¤­³¡¤À©Ò²Õ¦¨¡A¤À§O¬°¨â­Ó£\1¡B¨â­Ó£]2¤Î¤@­Ó£^2¡C©óA«¬£^-Ói°ò¤B»Ä¨üÅé¤W¦³£^-Ói°ò¤B»Ä¨üÅ骺µ²¦X¦ì¸m (GABA site)¡A£^-®ò°ò¤B»ÄÃþÃĪ«¥iÂǥѪ½±µµ²¦X¸Ó¦ì¸m©Î¶¡±µ¨Ï£^-Ói°ò¤B»Äµ²¦X¦Ü¸Ó¦ì¸m¡A¦¹®É´âÂ÷¤l³q¹D±o¥H¶}±Ò¡A´âÂ÷¤lªº¬y°Ê¦]¦Ó¼W¥[¡A³y¦¨¤¤¼Ï¨t²Îªº¹L·¥¤Æ¡A²£¥Í¤¤¼Ï¨t²Îªº§í¨î§@¥Î¡AÂǦ¹¹F¨ìÁ{§É¤W§ÜÅöíwªºªvÀø®ÄªG[4]¡C

¹Ï1. £^-®ò°ò¤B»Äºc³y¹Ï

¹Ï¤ù¨Ó·½¡Gºû°ò¦Ê¬ì

¹Ï2. A«¬£^-Ói°ò¤B»Ä¨üÅé²¹Ï

¹Ï¤ù¨Ó·½¡Gºû°ò¦Ê¬ì

¥»®×¨tª§±M§Q»P¥D­n¤Æ¾Çºc³y

¥»®×¨tª§±M§Q¦³¤G¥ó¡A¬°¬ü°ê±M§Q²Ä6,197, 819¸¹ ¡]'819±M§Q¡^ »P¬ü°ê¦A»âÃÒ±M§Q²Ä41,920¸¹ (RE'920±M§Q) [5]¡A'819±M§Q¤§¥Ó½Ð±M§Q½d³òÁ`¦@¦³4¶µ¡ARE'920±M§Q¤§¥Ó½Ð±M§Q½d³òÁ`¦@¦³25¶µ¡A¨ä¤¤¡A'819±M§Q¤¤¤§¥Ó½Ð±M§Q½d³ò²Ä1¶µ»P²Ä2¶µ³Ì¨ã¥Nªí©Ê¡A¤@¨Ö¦C¥X¦p¤U¡G

1. A compound of the formula S ¡V (+) ¡V 4 ¡V amino ¡V 3 ¡V ( 2 ¡V methylpropyl ) butanoic acid as a single optical isomer.

2. 4 ¡V amino ¡V 3 ¡V ( 2 ¡V methylpropyl ) butanoic acid , or a pharmaceutically acceptable salt thereof.

'819±M§Q¤§¥Ó½Ð±M§Q½d³ò²Ä1¶µ©Ò«ü¤§S ¡V (+) ¡V 4 ¡V amino ¡V 3 ¡V ( 2 ¡V methylpropyl ) butanoic acidºc³y¬O3-²§¤B°ò£^-Ói°ò¤B»Ä (3-isobutyl GABA) ¥B¥u­­¨î©ó¥ú¾Ç²§ºcª«¤¤ªºS²ÕºA¡A¦¹S²ÕºAºc³y¤SºÙ¬°´¶·ç¤ÚªL (¹Ï3) ¡A¬ÛÃö°Ó«~¬°Lyrica—û¡A2004¦~©ó¬ü°ê¥ÑFDA®Ö­ã¤W¥«¡C'819±M§Q¤§¥Ó½Ð±M§Q½d³ò²Ä2¶µºc³yªº3-²§¤B°ò£^-Ói°ò¤B»Ä«h¨Ã¥¼­­¨î¨äºc³y¬°¦óºØ²ÕºA¡A¦]¦¹¡A¥Ó½Ð±M§Q½d³ò²Ä2¶µªºÅv§Q½d³ò¤j©ó²Ä1¶µ......

¡i¥»¤å¥¼§¹¡A§¹¾ã¤º®e½Ð¨£¡m¥_¬ü´¼Åv³ø¡n337´Á¡GÅöíw¯gÃĪ«¤Æ¾Çºc³yªºÅã¦Ó©ö¨£©Ê¡GPfizer Inc. v. Teva Pharmaceuticals USA, Inc.(Fed. Cir. 2014)¡j

¡°¦p±ýÂà¸ü¥»¤å¡A½Ð»P¥_¬ü´¼Åv³øÁpµ¸

 
USPTO¸Õ¦æ¥HEmail±Hµo¦~¶O¤íú¬ÛÃö©x¨ç
¶ÀÄõ¶{¡þ¥_¬ü´¼Åv¡@´¼Åvªk³W¬ã¨s²Õ
¬ü°ê±M§Q°Ó¼Ð§½ (USPTO) ¤½§i·s¸Õ¿ì­pµe¡AÀò­ã°Ñ¥[ªº¬ü°ê±ÂÅv±M§Q©Ò¦³Åv¤H¡A­Y¦³¨ì´Á¦~¶O¥¼©ó©x¤è´Á­­¤é«eú¥æ¡B¥¼©ó¼e­­´Á¤º¸É±Ï¡A±N¥i¦¬¨ìUSPTO Email±Hµoªº´£¿ô¨ç¡B³qª¾¨ç¡C

USPTO 2023¦~5¤ë30¤é©ó¸Ó§½¡m±M§Q¤½³ø¡n¡]Official Gazette for Patents¡^µo¥¬·s¸Õ¿ì­pµe[1]¡AÀò­ã°Ñ¥[ªº¬ü°ê±ÂÅv±M§Q©Ò¦³Åv¤H¡A¥i¦¬¨ìUSPTO Email±Hµoªº¦~¶O¥¼Ãº¯Ç´£¿ô¨ç¡]Maintenance Fee Reminder¡^¡B¤Î¥¼Ãº¦~¶O­P±M§QÅv©¡´Á®ø·À³qª¾¨ç¡]Notices of Patent Expiration¡^¡C

»Ýª`·Nªº¬O¡AUSPTO¨Ìªk¨ÃµL¸q°È³qª¾±M§Q©Ò¦³Åv¤H¦~¶O§Y±N¨ì´Á¡C½T»{¤w¨Ì³W©wú¥æ¦~¶O¡BÁ×§K±M§QÅv¦]¥¼Ãº¦~¶O©¡´Á®ø·À¡A¹ê»Ú¤W¬O¬ü°ê±M§Q©Ò¦³Åv¤H¦Û¤vÀ³ºÉªº³d¥ô¡C¤£½×¬O¯È¥»©Î¹q¤l§Î¦¡ªº´£¿ô¨ç¡B³qª¾¨ç¡A§Y¨Ï©x¨ç¤º®e°O¸ü¦³»~¡B¤å¥ó±H°e¥X¿ù¡B¥¼»sµo©Î¤Ó±ß»sµo©x¨ç¡A¥¼¨Ìªk©ó©x¤è´Á­­¤ºÃº¥æ¦~¶O©Î¸É±ÏªÌ¡A³£¤£¯à¥H¦¹¬°¥ÑÀò±o¼e§K¡A¬ÛÃö¬ü°ê±M§QÅv¤´·|¦]¬°±M§Q©Ò¦³Åv¤H¥¼Ãº¦~¶O¨Ìªk©¡´Á®ø·À¡C

¸Õ¦æ¿ìªk»P¬J¦³§@ªkªº¤£¦P

¬ü°êµo©ú±M§Q±ÂÅv«á¡A·Q§¹¾ã¨É¦³20¦~ªº±M§QÅv«OÅ@¡A»Ýú§¹¤T´Á¦~¶O¡]Maintenance Fee¡^¡C¥ô¤@´Á¦~¶O¥¼©ó³W©wªº¥b¦~´Á¶¡Ãº¯Ç¡AUSPTO´N·|±Hµo¦~¶O¥¼Ãº¯Ç´£¿ô¨ç¡A­Y«áÄò¥b¦~ªº¼e­­´Á¤º¤]¥¼¥[¥H¸É±Ï¡AUSPTO·|¦A±Hµo±M§QÅv©¡´Á®ø·À³qª¾¨ç¡C

¥ý«eUSPTO¥u´£¨Ñ¯È¥»ªº´£¿ô¨ç¡B³qª¾¨ç±HµoªA°È¡C±M§Q±ÂÅv«á¡A­Y±M§Q©Ò¦³Åv¤H´¿¨Ì37 CFR 1.363«ü©w¤@Customer Number§@¨ä¦~¶O¦a§}¡]fee address for maintenance fee purposes¡^[2]¡A³o¨Ç©x¨ç¯È¥»·|±H¨ì¸ÓCustomer Numberµn¿ýªº¹êÅé¦a§}¡C­Y±M§Q©Ò¦³Åv¤H¥¼´¿«ü©w¦~¶O¦a§}¡A³o¨Ç©x¨ç¯È¥»·|±H¨ì®×¥ó­ìµn¿ýªº³q°T¦a§}¡]correspondence address of record¡^¡C

­YÀò­ã°Ñ¥[¥»¶µ¿ìªk¡AUSPTO·|§â³oÃþ©x¨ç¥Hªþ¥ó§Î¦¡±HEmail¨ì¦~¶O¦a§}µn°OªºEmail«H½c¡A¤º®e©M¯È¥»´£¿ô¨ç¡B³qª¾¨ç§¹¥þ¬Û¦P¡A¦ý¥u¥HEmail±H°e¡A¤£·|¥t¦³¯È¥»´£¿ô¨ç¡B³qª¾¨ç±Hµo¡C­YCustomer Numberµn°O¦³½Æ¼Æ­ÓEmail¦a§}¡A¥þ³¡µn°OªºEmail«H½c³£·|¦¬¨ì³qª¾¡C

¸Õ¦æ¿ìªk¥Ó½Ð¤Î¹ê¬I­nÂI

³o¶µ¸Õ¦æ¿ìªk¤w©ó2023¦~5¤ë30¤éUSPTO¤½§i¤§¤é¥Í®Ä¡A¹w©w¸Õ¿ì¦Ü¤Ö6­Ó¤ë¡Cµø¨ä¦¨®Ä¡AUSPTO¤]¥i¯à´£«eµ²§ô¸Õ¿ì¡BÅܧó¸Õ¦æ¿ìªk¡C

­Y±M§Q©Ò¦³Åv¤H¦³·N°Ñ¥[¥»¶µ¿ìªk¡A­º¥ý»Ý½T»{¤w¨ú±oUSPTO®ÖµoªºCustomer Number¡A¦ÓCustomer Number¦³¸j©wªºEmail¦a§}¡A¥B¤w¨Ì³W©w«ü©w¸ÓCustomer Number§@¨ä¬ü°ê±ÂÅv±M§Qªº¦~¶O¦a§}¡CµM«á¦A¨Ì«ü©w®æ¦¡¼gEmail±H¨ìUSPTO¦¬¥óµ¡¤f¥Ó½Ð°Ñ¥[¡]Opt-in¡^¡G

(1) Email±H¨ìRADHelpdesk@uspto.gov¡F

(2) ¥D¦®Äæ¶ñ¡uMF Notices Email Pilot Program¡v¡F

(3) ¤º®e¼g©ú©m¦W¡B¹q¸Ü¸¹½X¡BCustomer Number¡A¨Ã¥HS-Signature¹q¤lñ¦W¡C­Y¦~¶O¦a§}¬°ªk¤H¡]¨Ò¡G¦~¶O¤½¥q¡^©Ò¦³¡A¤º®e¨Ã»Ý¼g©ú²Õ´¦WºÙ¡B¥Nªí¥Ó½ÐªººÞ²z¤H­û¡]officer¡^¾ºÙ¡A¤Î¸Ó¥NªíºÞ²z¤H­ûÀò±ÂÅv¥i¥Nªí¥Ó½ÐªºÁn©ú¤å¦r¡F¥B

(4) ±H¥ó¤H³¡¤À¡A°²¨Ï¦~¶O¦a§}¦¬¥ó¤H¬O­Ó¤H¡A¶·¥Ñ¸Ó­û±H°e¥Ó½ÐEmail¡F­Y¦~¶O¦a§}¬°ªk¤H©Ò¦³¡A«hÀ³¥Ñ«e­z¥Nªí¥Ó½ÐªººÞ²z¤H­û±Hµo¥Ó½ÐEmail¡C

USPTO¦¬¥ó«á·|¥ý½T»{¬O§_²Å¦X¦U¶µ³W©w¡AµL°ÝÃD§Y·|¦^ÂнT»{­ã¤©°Ñ¥[¡A¤§«á¬ÛÃö´£¿ô¨ç¡B³qª¾¨ç¥þ¼ÆÂରEmail±Hµo¡C­n¬O¦~¶O¦a§}¬°ªk¤H©Ò¦³¡AUSPTO¦³¥i¯à¦A¨ç½Ð¸Óªk¤H½T»{¥Nªí¥Ó½ÐªÌ¬O§_¯u¦³Åv­­§@¦¹¨M©w¡C

¡i¥»¤å¥¼§¹¡A§¹¾ã¤º®e½Ð¨£¡m¥_¬ü´¼Åv³ø¡n337´Á¡GUSPTO¸Õ¦æ¥HEmail±Hµo¦~¶O¤íú¬ÛÃö©x¨ç¡j

¡°¦p±ýÂà¸ü¥»¤å¡A½Ð»P¥_¬ü´¼Åv³øÁpµ¸

³Æµù¡G

1.New Opt-In Pilot Program for Receipt of Maintenance Fee Reminder and Expiration Notices by Email¡A½Ð¨£https://patentsgazette.uspto.gov/week22/OG/TOC.htm#ref11¡C

2.±M§Q±ÂÅv«á¡A¥u¯à«ü©wCustomer Number§@¨ä±M§Qªº¦~¶O¦a§}¡ACustomer Number»Ý¦VUSPTO¥Ó½Ð¡A¦³¤@©wªº¸ê®æ­­¨î¡C¨ú±oUSPTO®ÖµoªºCustomer Number«á¡A§Y¨Ï¥i§Q¥ÎUSPTO¨î¦¡ªí®æPTO/SB/47©ÎPTO/AIA/47«ü©w¦~¶O¦a§}¡C

 
Àb«È§ðÀ»¦A½·s¡G¥ø·~¤£¥i¤£ª¾ªº¸ê¦w§ðÀ»¤âªk
§dºÑ®Z¢¬¥_¬ü´¼Åv³ø¡@½s¿è³¡

®Ú¾ÚÁͶլì§Þµo¥¬ªº¡m2022¦~«×¸ê¦wÁ`µû³ø§i¡n¡A¥h¦~¬OÀb«È¬°¤F´£®¶Àò§Q¦Ó¡u¾Ä¤O¤@·i¡vªº¤@¦~¡A¸ê¦w«Â¯Ù¾ãÅé°»´ú¼Æ¶q¤j´T¼W¥[55%¡AÀb«ÈµL®t§O¦a§ðÀ»©Ò¦³²£·~ªº®ø¶OªÌ©M¥ø·~¾÷ºc¡A³y¦¨¤wÄdºIªº´c·Nµ{¦¡Àɮ׼ƶq¼É¼W242%¡C¬Ì±¡´Á¶¡¶}±Ò¤F©~®a¿ì¤½ªº·s¤u§@¼Ò¦¡¡A«oÅýÀb«È±o¥H§Q¥Î»·ºÝªA°È¬ð¯}¥ø·~¨¾½u¡A¨Ã³z¹L«áªùµ{¦¡§ðÀ»ºô¯¸¦øªA¾¹¥­¥xªºº|¬}¡Cªk°È³¡½Õ¬d§½½Õ¬d©x§õ«É¸©¥H¤T¶µÀb«È¤J«Iªº¯u¹ê®×¨Ò¡A©IÆ~¥ø·~¯}¸ÑÀb«È¤âªk¡B¤p¤ß¨t²Î²¨º|©Ò±a¨Óªº¸ê¦w­·ÀI¡C

¤ÏÂеo¥Íªººô­¶¤º®e¸m´«

¦^ÅU2022¦~8¤ëªì®É¡A¬ü°ê²³Ä³°|ijªø»p¬¥¦è¡]Nancy Pelosi¡^©è¥x¶i¦æ³X°Ý¡A·í®É¤£¶ÈÁ`²Î©²¡B¥~¥æ³¡¡B°ê¨¾³¡ªººô¯¸³£³QÀb«ÈÅõºÈ¡A´N³s¶W°Ó¡B¥xÅK¤õ¨®¯¸µ¥³Bªº¹qµøÀð¤]¾D¨ü§ðÀ»¡A°ª¶¯¥«Àô«O§½ºô¯¸¬Æ¦Ü¥X²{±¾º¡¤­¬PºXªºµe­±¡A¦æ¬F°|Áö¨Æ¥ý¤w±Ò°Êĵ§Ù±M®×¡A¦ýºô¸ô§ðÀ»Á`¬y¶q¶W¹L1.5¸U¡A¶W¥X¹L¥h³æ¤é³Ì°ª§ðÀ»¶qªº23­¿¡I

§õ«É¸©ªí¥Ü¡A¤ÏÂеo¥Íªººô­¶¤º®e¸m´«Åã¥Ü¦øªA¾¹¤w¦s¦bº|¬}¡A¹ï¨ü®`³æ¦ì±N·|³y¦¨¦h¶µ¸ê¦w½ÄÀ»¡A¥]¬A¿y¹Ü±b¸¹Åv­­¡A¶i¦æ²§±`·s¼W©Î§R°£±b¸¹¡B²M°£¬ö¿ý©Î­«³]±K½X¡C

¸g½Õ¬d§½½Õ¬d¡A¦b¨ü®`³æ¦ìºô­¶¤º®e¾D¨ì¸m´«¤§«e¤@­Ó¤ë¡Aºô¸ô¦øªA¾¹´N¤@ª½³°Äò¨ü¨ì´c·Nµ{¦¡§ðÀ»¡A©Î¬O¶}±Ò»·ºÝ®à­±ªA°È¡A¨Ã¸m¤J¦UºØ¤u¨ãµ{¦¡¨ì¦øªA¾¹·í¤¤¡A§@¬°§ðÀ»¸õªOªºÄw³Æ¬¡°Ê¡C§õ«É¸©±j½Õ¡AÀb«È¸m´«ºô­¶¤º®e¡A°£¤Fªí­±¤W¥i¥H¬Ý¨ì´c·N¼J§Ëªº¦r²´¡A§ó­nª`·Nªº¬OÀb«È¤w¦³¯à¤O±N´c·Nµ{¦¡©Mµê°²¸ê°T¸m¤J¹q¸£¤¤¡A¥i¯àÅý¨Ï¥ÎªÌ¨ü¨ì»~¾É¡A¬Æ¦Ü¦³¸ê®Æ¥~¬ªªº­·ÀI¡C

°w¹ï¤ÏÂеo¥Íªººô­¶¤º®e¸m´«¡A§õ«É¸©«ØÄ³¦U³æ¦ìÀ³«Ø¥ß¸ê¦w¨Æ¥óÀ³ÅܳB¸m¤Î³q³ø¾÷¨î¡A³]¸m¦Û°Ê°»´úÀɮײ§°Êªº¤u¨ã¡A­Yµo²{ºô­¶¤º®e¾D¨ìÀb«È¸m´«¡AÀ³¥ß¨è¤U¬[«O¥þÃÒ¾Ú¡AÁ×§KÀb«È§Q¥Î¬J¦³ªºº|¬}Ä~Äò§ðÀ»¡A¨Ã¤W¶Çºû­×¤¤ªºÀRºAµe­±¡A«Ý­×´_¤§«á¦A«ì´_­ì¥»ªººô­¶µe­±¡A­«·s¤W¬[«áÀ³«ùÄòÆ[¹î¬O§_¤´¦³§ðÀ»±¡ªpµo¥Í¡C

§õ«É¸©¤]´£¿ô¡AÁ×§K±N¾÷±Ó¸ê®Æ¼ÉÅS©ó¶}©ñºô¸ôÀô¹Ò¤¤¡AÀ³¸Ó©w´Á½LÂI¹q¸£¤¤¾÷±Ó¸ê®Æ¦s©ñªº¤è¦¡»P¦ì¸m¡A¨Ã¾A·í¤©¥H¥[±K«OÅ@¡A¨Ï¥ÎªÌ©MºÞ²z¤H­û¤]À³¸ÓÀH®Éª`·N¡A¹q¸£¤¤¬O§_¥X²{­¯¥Íªº±b¸¹©M¤£©úªºÀɮסC³Ì­«­nªº¬O¡A©ó¨t²Î¶}µoªì´Á´NÀ³¯Ç¤J¸ê¦w¦Ò¶q¡AÀb«È¤J«I«á¶i¦æ¸É±Ï¥u¬O¤`¦Ï¸É¨c¦Ó¤w¡C

³sÂê²_³´ªº»·ºÝµn¤J¸õªO

²Ä¤GºØ±`¨£ªº¸ê¦w§ðÀ»¬O³sÂê²_³´ªº»·ºÝµn¤J¸õªO¡A¥ç§Y³z¹L¦h¶¥¼hªº¸õªO¶i¦æºô¸ô§ðÀ»¡AÅýÀb«È±o¥H²V²cÂܸñ¡A¤×¨ä¦b2021~2022¦~¥þ¥x©~®a¿ì¤½®É´Á®É¦³©Ò»D¡C

¬Y³æ¦ì¨Ï¥ÎªÌ¹îı»·ºÝ³s½uºô³tÅܱo«ÜºC¡A¸g¬d«áµo²{¤@¤p®É¤º¦³°ª¹F¼Æ¤Q¸U¦¸ªº»·ºÝ³s½u¼Æ¡A¥ß§Y«Ê³¬»·ºÝ³s½uªA°È¨Ã³ø®×¡A½Õ¬d§½½Õ¬dµo²{¡A¸Ó³æ¦ìªº»·ºÝ³s½uºô¸ô¦¨¬°Àb«È³sÂê§ðÀ»ªº¸õªO¤§¤@¡C§õ«É¸©«ü¥X¡A²_¬°§ðÀ»¸õªOªº³æ¦ì¡A¤£¤À²£·~¡B¤£¤À³W¼Ò©M³]³Æ¥\¯à¥Î³~¡A³£¥i¯à¦¨¬°Àb«È§ðÀ»ªº¸õªO¡A¦@¦PÂI¬O·í®É³B©ó©~®a¿ì¤½®É´Á¡Aªø®É¶¡¶}±Ò»·ºÝ³s½uªA°È¡Aªø´Á¶}¾÷¤S¥¼Åܧó±K½X¡A¥Ñ©ó»·ºÝ³s½uªA°È¥u¨Ï¥Î±b¸¹±K½X¶i¦æÅçÃÒ¡AÀb«È«Ü®e©ö³z¹L¼É¤O²q´ú§ðÀ»¡A¥ý¨ú±o¨Ï¥ÎªÌÅv­­¦A¨ú±oºÞ²zªÌÅv­­¡A¬Æ¦Ü¦bºô¸ô¤W´N¥i¥H§ä¨ì¤J«I»·ºÝ³s½uªA°Èªº±Ð¾Ç¼v¤ù¡C

¥Ñ©óÀb«È¤u¨ã¤éº¥®e©ö¨ú±o¡A­°§C¤j³W¼ÒÀb«È§ðÀ»ªºªùÂe¡A¥ô¦ó³sºô³]³Æ³£¦³¥i¯à¦¨¬°³Q§ðÀ»ªº¹ï¶H¡A«ØÄ³À³¹ï»·ºÝ³s½u¨Ó·½ºÝ¥[¥H­­¨î¡BÃö³¬«D¥²­nªºªA°È¡A¨Ã½T«O¨¾¤õÀ𥿽T°t¸m¡B±j¤Æ±K½X±j«×©Î±Ò¥Î¦h¦]¯ÀÅçÃÒ¡C

¦Û¤v°Ê°_¨Óªººô¸ô¦Lªí¾÷

ÀHµÛ¼Æ¦ì¤Æ¶i¨B¡A³sºô¦Lªí¾÷Åý¨Ï¥ÎªÌ¥i³z¹Lºô¸ô¶i¦æ³]©w©M¸ê®Æ¦s¨ú¡A¦P®É¤]´£¨Ñ¤FÀb«È§ðÀ»ªº¾÷·|¡A¥u­n§Q¥Î¨t²Îº|¬}©Î¬O±j«×¤£°÷ªº±K½X¡A´N¯à±q»·ºÝ¾Þ±±¦Lªí¾÷°µ¬°¸õªO¡A¦A§ðÀ»¤º³¡¹q¸£³y¦¨¦M®`¡C

¤µ¦~4¤ë¬ü°ê²³Ä³°|ijªø³Á¥d¿ü¡]Kevin McCarthy¡^¦b¥[¦{»PÁ`²Î½²­^¤å·|­±®É¡A¥xÆW´N´¿µo¥ÍÀb«È§ðÀ»ºô¸ô¦Lªí¾÷¡A¨Ã¦L¥X¤j¶q²Î¾Ô¤å«Åªº¸ê¦w¨Æ¥ó¡C§õ«É¸©«ü¥X¡AÀb«È±`±`¿ï¦b¿ïÁ|´Á¶¡¡B­«¤j¬Fµ¦±À¦æ¡B­«­n¬Fªv¤H¤h¦æµ{¡BªÀ·|­«¤j¨Æ¥óµ¥ÃöÁä®É¨è¶i¦æ¤j³W¼Ò§ðÀ»¡A¨Ã¦b³sÄò°²´Á©Î¥b©]µo°Ê¡A§Q¥Îºô¸ô¦Lªí¾÷³]©w·¥¤j¶qªº¦C¦L¤u§@¡AÅý¨ü®`³æ¦ìÃø¥H§Y®Éµo²{¡A¥Øªº¬O³y¦¨ªÀ·|¤j²³ªº®£·W¤ß²z©MÁÖ½×ÃϵM¡AÅý¹Ò¥~ªºÀb«È¥H§C¦¨¥»¹F¨ì¤j³W¼Òªº¥Ü«Â®ÄªG¡C

¥Ñ©ó²{¦b¤j³¡¤Àºô¸ô¦Lªí¾÷³£¨ã³Æ»·ºÝ¦C¦L¥\¯à¡A¿é¤JºÞ²zªÌ±b¸¹±K½X«á´N¯à¤W¶Ç±ý¦C¦LªºÀɮסAÀb«ÈµL¶·°ª²`ªº§Þ³N¡A¥u­n·j´M¤½¶}©T©wIP¦ì¸mªº¦Lªí¾÷¡A¦A²q´ú¯}¸Ñ±K½X§Y¥i°õ¦æ»·ºÝ¦C¦L¡A¤]¦³¥i¯à¬O³z¹L¨t²Îº|¬}¡Aª½±µÂ¶¹LÅçÃÒ¾÷¨î¡BÀò±oºÞ²zªÌÅv­­¡A°£¤F±j¤Æª«Ápºô³]³Æªº±K½X±j«×¡A§õ«É¸©«ØÄ³ÁÙ­n­­¨î¦s¨ú¨Ó·½¡BºÊ±±¦s¨ú¬ö¿ý¡A¥­®É¤]­n¦hª`·N¬O§_¦³¨t²Îªºº|¬}¤½§i©M­×¸Éµ{¦¡¡A¤~¯à¦³®Ä©è¾×Àb«È§ðÀ»¡C

§õ«É¸©¤]´£¿ô¡A¥­®É´N­n¦hÆ[¹îºô¸ô¬y¶q¬O§_²§±`¡BÆ[¹î¹q¸£¤º³¡¬O§_¥X²{¤£©úªº±b¸¹©ÎÀÉ®×¼W´î¡A¤~¯à¦³®Ä±j¤Æ¸ê¦w«O»Ù¡C­YµL¬G¨ú±o¡B§R°£©ÎÅܧó¥L¤H¹q¸£©Î¨ä¬ÛÃö³]³Æ¤§¹qºÏ¬ö¿ý¡A¥i¯àIJ¥Ç¦Dªkªº§«®`¹q¸£¨Ï¥Î¸o¡A±N¥i³B¤­¦~¥H¤U¦³´Á®{¦D©Î¨Ö¬ì60¸U¤¸¥H¤U»@ª÷¡C

¡i¥»¤å¥¼§¹¡A§¹¾ã¤º®e½Ð¨£¡m¥_¬ü´¼Åv³ø¡n337´Á¡GÀb«È§ðÀ»¦A½·s¡G¥ø·~¤£¥i¤£ª¾ªº¸ê¦w§ðÀ»¤âªk¡j

¡°¦p±ýÂà¸ü¥»¤å¡A½Ð»P¥_¬ü´¼Åv³øÁpµ¸

¸ê®Æ¨Ó·½¡G

1.2023/7/17¡A¸gÀÙ³¡¤¤¤p¥ø·~³B¡m·s³ÐÀç·~¯µ±K»P¸ê¦w«O»Ùµ¦²¤¡n¡A§õ«É¸©Â²³ø¡C

2.2023/3/16¡AÁͶլì§Þ¡G2022¦~ºô¸ô«Â¯Ù°»´ú¼Æ¶q 1,460 »õ³Ð¾ú¥v·s°ª¡C

 
2035¦~¥þ²y¹q°Ê¨®¤ñ­«±N¹F¤E¦¨¡A¬ü¾¥¦¨¬°¼öªù§ë¸ê¦aÂI
§dºÑ®Z¢¬¥_¬ü´¼Åv³ø¡@½s¿è³¡
¹q°Ê¨®®ö¼é¿³°_¡A¹w­p2035¦~¥þ²y¹q°Ê¨®¤ñ­«±N¹F¤E¦¨¡C¥Ø«e¥þ²y¹q°Ê¨®¥D­n²£·~Ãì´x´¤¦b¤¤°ê¤â¤¤¡A¬ü°êªñ´Á³z¹L¡m­°§C³q¿±ªk®×¡n¡]Inflation Reduction Act¡FIRA¡^²½¥X¹q°Ê¨®¯²µ|·s³W¡A§l¤Þ¹q°Ê¨®²£·~Ãì«e©¹¬ü°ê§ë¸ê¡B¥ø¹Ï¥[³t¬ü°ê¹q°Ê¤Æ¤É¯Å¸}¨B¡C¥t¤@¤è­±¡A¾¥¦è­ô¨ü´f©ó¦a½t¬Fªv»P¬ü¾¥¥[¶T©ö¨ó©w¡A¦b¯S´µ©Ô¡]Tesla¡^ªº¸¹¥l±a°Ê¤U¡A¹q°Ê¨®¨ÑÀ³Ãì·~ªÌ¬Ý¤¤¾¥¦è­ôµo®i¼ç¤O¡A¦Ò¶q­u¾¥¦è­ô³]¼t¡C

¹Ï¤@¡B¸ê¸Û¬ì§Þ²£·~¬ã¨s¤¤¤ß¥D¥ô¾G¶²¶©¤À¨É¬ü°ê¹q°Ê¨®¥«³õµo®iÁͶաC

§dºÑ®Z¡þÄá¼v

2035¦~¹q°Ê¨®¤ñ­«±N¹F¤E¦¨

¥þ²y¹q°Ê¨®¡]xEV¡^¥«³õªñ¦~ºû«ù°ª³t¦¨ªø¡A¥¿¦b³v¨B¨ú¥N¶Ç²Îªº¤º¿U¾÷¨T¨®¡]ICE¡^¡C¸ê¸Û¬ì§Þ²£·~¬ã¨s¤¤¤ß¹w¦ô¡A2022¦~¥þ²y¹q°Ê¨®´Ú¡A¥]§t²V©M¹q°Ê¨T¨®¡]HEV¡^¡B´¡¹q¦¡²V©M°Ê¤O¨T¨®¡]PHEV¡^¡B¹q¦À°Ê¤O¨T¨®¡]BEV¡^µ¥¹q°Ê¨®ºØ¡A¾ãÅ饫³õ¦X­p¹F¨ì1,845¸U½ø¡A¥e¥þ²y¨T¨®¥«³õ¤ñ­«22.8%¡C¥þ²y¥D­n¨®¼t³°Äò¦b2040¦~¥H«e²×¤î¥Í²£¿Uªo¨®¡A¹w­p2035¦~¹q°Ê¨®¤ñ­«±N¹F¤E¦¨¡C¥Ñ©ó·P´ú¾¹¡Bºtºâªkµ¥§Þ³NÁͩ󦨼ô¡ALevel 1/2¡BLevel 3¦Û°Ê¾r¾p¸Ñ¨M¤è®×¥Ñ»¨µØ¨®¥«³õ§Ö³t¦V¤¤§C¶¥¨T¨®¥«³õº¯³z¡A2021¦~¹q°Ê¨®º¯³z²v©ó¤w¹F48%¡AÀHµÛLevel 3¥H¤W¨t²Îº¯³z²v«ùÄòÂX¤j¡A¹w­p2035¦~¦Û°Ê¾r¾p¨t²Îº¯³z²v±N¹F70%¡C

¹Ï¤G¡B2035¦~¥þ²y¨T¨®¥«³õ¹q°Ê¤Æ¡]¥ª¡^»P¦Û°Ê¾r¾pº¯³z²v¤ñ­«¹w¦ô

¹Ï¤ù¨Ó·½¡GStrategy&¡F¸ê¸Û¬ì§Þ²£·~¬ã¨s¤¤¤ß¾ã²z¡A2023/07

¬ü°ê¹q°Ê¨®²£·~¦¨ªø¼ç¤O¤j

¦^ÅU2022¦~¹q°Ê¨®¾P°â¶q¡A¥Ñ©ó¤¤°êªø¹F13¦~ªº·s¯à·½¨T¨®¸É§U©ó¤µ¦~°h³õ©Ò²£¥Íªº´£«eÁʨ®¼é¡A2022¦~¤¤°ê¹q°Ê¨®¾P¶q¹F618¸U½ø¡B¸û2021¦~¦¨ªø82%¡F¦Ó2022¦~¬ü°ê¹q°Ê¨®¾P¶q«h¦³99.4¸U½ø ¡C¸ê¸Û¬ì§Þ²£·~¬ã¨s¤¤¤ß¥D¥ô¾G¶²¶©Æ[¹î¡A¬ü°ê¬°¥þ²y²Ä¤G¤j¨T¨®¥«³õº[¥Í²£°ò¦a¡A2022¦~¨T¨®¥«³õ³W¼Ò¹F¨ì1,365¸U½ø¡B¨T¨®¦~²£¶q¬°976¸U¡A¦Ó¥þ²y¹q°Ê¨®¥«³õªñ¦~°ª³t¦¨ªø¡A¬ü°ê¦P®É¤]¬O¥þ²y²Ä¤G¤j³æ¤@°ê®a¹q°Ê¨®¥«³õ¡A¥u¤£¹L¹q°Ê¨®¥«³õº¯³z²v«o¬Û¸û¤¤°ê¤j³°»P¼Ú¬w§C¡AÅã¥Ü¬ü°ê¦s¦b§ó¤jªº¹q°Ê¨®¥«³õ¦¨ªøªÅ¶¡¡A©M§ó§Öªº¦¨ªø¼ç¤O¡C

±q¾ãÅé¾P°â¶qÆ[¹î¡A¬ü°ê¹q°Ê¨®¥«³õ¥¿¥[³t´ÂBEVÂ૬µo®i¡A±q2020¦~¥e¬ü°ê¹q°Ê¨®¥«³õ¾P°â¶q32%¡A´£°ª¨ì2022¦~ªº42%¡C¨ä¤¤Tesla¤´¬°³Ì¥D­nªº«~µP¡A¥«¥e²v¤´°ª¹F30.3%¡A¨ä¦¸«h¬OToyota¡]29.4%¡^¡BHyundai-Kia¡]10.6%¡^¡BFord¡]9.7%¡^¡BHonda¡]5.6%¡^¡C«e¤­¤j¨®¼t¤¤°£Hyundai-Kia¤§¥~¡A¨ä¥L¨®¼t§¡¥HHEV¨®«¬¬°¥D¡A¶Ç²Î¨®¼t¦b¹q°Ê¤ÆªºÂ૬³t«×½wºC¡AEV¤Æ¤ñ­«´¶¹M¤£¤Î10%¡A³y¨®·s¶Õ¤O«h³B©óµÞªÞ´Á¡C

¹Ï¤T¡B¬ü°ê¹q°Ê¨®¥«³õ¾P°â¶qµo®iÁͶÕ

¹Ï¤ù¨Ó·½¡G¸ê¸Û¬ì§Þ²£·~¬ã¨s¤¤¤ß¾ã²z¡A2023/07

IRA¤Þ¾É¥ø·~­u¬ü§ë¸ê¹q°Ê¨®

¬°¹F¦¨2030¦~·Å«Ç®ðÅ鱯©ñ¶q¸û2005¦~­°§C40%ªº¥Ø¼Ð¡A¬ü°êÁ`²Î«ôµn¦b2022¦~8¤ëñ¸p¡m­°§C³q¿±ªk®×¡n¡A¸Óªk®×±N¦b¥¼¨Ó¤Q¦~¤º±N´£¼·3,690»õ¬ü¤¸§ë¤J¯à·½¦w¥þ»P®ð­ÔÅܾE¡A¨Ã´£¨Ñ®ø¶OªÌÁʶR¹q°Ê¨®µ|¦¬©è§Kµ¥¿EÀy±¹¬I¡A¥H¥[³t¬ü°ê²b¹sºÒ±Æ¸}¨B¡C¥Ñ©óIRA¹ï©ó¹q°Ê¨®¸É§U¥[³]¤F¹q¦À§÷®Æ»P»s³y©Ò¦b¦aªº­­¨î¡A«P¨Ï¹q°Ê¨®¼t©M¬ÛÃö¹s²Õ¥ó¼t°Ó«e©¹¬ü°êÂX²£¡B´Nªñ¨ÑÀ³¥«³õ»Ý¨D¡A¹q¦À¼t¤]»P¨®¼t¦X¸ê³]¥ß¹q¦À²Õ¸Ë¼t¡A¦b¬ü°ê­««Ø«D¤¤¨tªºÄq²£¡B§÷®Æ¨ÑÀ³Ãì¡A³£¦¨¬°¥[³t¬ü°ê¹q°Ê¤Æ¤É¯ÅÂ૬ªºÃöÁä¦]¯À¡C

¡i¥»¤å¥¼§¹¡A§¹¾ã¤º®e½Ð¨£¡m¥_¬ü´¼Åv³ø¡n337´Á¡G2035¦~¥þ²y¹q°Ê¨®¤ñ­«±N¹F¤E¦¨¡A¬ü¾¥¦¨¬°¼öªù§ë¸ê¦aÂI¡j

¡°¦p±ýÂà¸ü¥»¤å¡A½Ð»P¥_¬ü´¼Åv³øÁpµ¸

 
¬ü°ê³Ì°ªªk°|¬°°Ó¼Ð«IÅv¹Ò¥~®Ä¤O¹º¬É½u¡G2023¦~Abitron Austria GmbH v. Hetronic Int'l, Inc.®×
·¨´¼³Ç¡þ¶³¬ì¤j¬ìªk©Ò±Ð±Â
¬ü°ê³Ì°ªªk°|1952¦~´¿§P¨M¡A¦b¬Y¨Ç±¡ªp¤U¡A¬ü°ê°Ó¼Ðªk¥i¥HºÞ¨ì¹Ò¥~ªº«IÅv¦æ¬°¡C¦¹«á¡A¤U¯Åªk°|¤À§Oµo®i¥X¤£¦P¼Ð·Ç¡C2021¦~¬ü°ê²Ä¤Q¨µ°jªk°|§P¨M¡A³Q§i¦b¼Ú¬wªº°Ó¼Ð«IÅv¶·½ßÀv¬ü°ê­ì§i¬ù9600¸U¬ü¤¸[1]¡C³Q§i¤W¶D«á¡A2023¦~6¤ë29¤é¡A¬ü°ê³Ì°ªªk°|¹ï§@¥XAbitron Austria GmbH v. Hetronic Int'l, Inc.®×§P¨M¡A»{¬°¤U¯Åªk°|µo®i¥X¨Óªº¼Ð·Ç¤£§´·í¡AÀ³¸Ó¥H¡u¬ü°ê¹Ò¤º°Ó·~¤Wªº«IÅv¨Ï¥Î¡v§@¬°§PÂ_°ò·Ç¡A¨M©w¬O§_¾A¥Î¬ü°ê°Ó¼Ðªk¡C

1952¦~ªºSteele v. Bulova Watch Co.®×

¬ü°ê³Ì°ªªk°|¦b1952¦~ªºSteele v. Bulova Watch Co.®×[2]¡A´¿¸g´£¥X¹LÁp¨¹°Ó¼Ðªkªº¹Ò¥~®Ä¤O°ÝÃD¡C·í®É³Ì°ªªk°|»{¬°¡AÁp¨¹°Ó¼Ðªk½T¹ê¥i¥H¦b¬Y¨Ç®É­Ô¡A¾A¥Î©ó¹Ò¥~¦æ¬°¡C¸Ó®×¤¤¡A¥Ñ©ó³Q§i¬O¬ü°ê¤½¥Á¡A¥B¨ä¦b¬ü°êÁʶR¤F³¡¤À«IÅv¹s¥ó¥X¤f¨ì¾¥¦è­ô²Õ¸Ë¡A¦Ó¨ä°²«_ªº¡uBulovas¡v¤â¿ö¤S¬y³q¦^¬ü°ê¡F¨ä²£«~¥i¯à·|¹ï¬ü°êªºBulovas¤½¥qªº°ÓÅA²£¥Í¼vÅT[3]¡C¦]¦¹¡A³Ì°ªªk°|»{¬°¡A±q¥»®×ªº¨Æ¹ê¨Ó¬Ý¡A³Q§iªº¦æ¬°¥i¥H¾A¥Î¬ü°êÁp¨¹°Ó¼Ðªk[4]¡C

¦b1952¦~Steele®×¥H¨Ó¡A¨ì©³­þ¨Ç¯A¤Î¸ó¹Ò«IÅvªº®×¥ó¥i¾A¥Î¬ü°ê°Ó¼Ðªk¡A¦U¨µ°jªk°|µo®i¥X¤£¦Pªº¼Ð·Ç¨Ó¥[¥H§PÂ_¡C

²Ä¤Q¨µ°jªk°|§P¨M¼Ú¬w«IÅv§P½ß¬ü°ê­ì§i9600¸U¬ü¤¸

¥»®×ªº·í¨Æ¤H¤@¤è¬°¬ü°ê¤½¥qHetronic¤½¥q¡A¥t¤@¤è¬°¤»®a¥~°ê¤½¥q¡A¦XºÙAbitron¤½¥q¡CHetronic¦b¬ü°ê¶ø§J©Ô²ü°¨¦è°Ï¦a°Ïªk°|´£§iAbitron¡A»{¬°¨ä«I®`¦Û¤vªº°Ó¼Ð¡Aºc¦¨²V²c»~»{¡C³Ì­«­nªº¬O¡AHetronic½Ð¨Dªº½ßÀvª÷¡A¥]§tAbitron²£«~¦b¥þ²y¾P°â³y¦¨ªº·l®`¡CAbitron «h»{¬°¡AHetronic½Ð¨Dªº½d³ò¡AÄÝ©ó¬ü°ê¹Ò¥~¨Æ°È¡A¤£¦b¬ü°ê°Ó¼Ðªk¾A¥Îªº½d³ò¡C

¦a°Ïªk°|»é¦^Abitronªº¥D±i¡A¦Ó³­¼f¹Î¨M©w§P½ßHetronic½ßÀvª÷¡A¨ä¤¤9600¸U¬ü¤¸Âk©S©óAbitron¦b¹Ò¥~¨Ï¥ÎHetronic°Ó¼Ð³y¦¨ªº·l®`¡C¦a°Ïªk°|¤]®Öµo¥Ã¤[¸T¨î¥O¡A¸T¤îAbitron¦b¹Ò¥~¨Ï¥ÎHetronic°Ó¼Ð¡C

¤W¶D«á¡A²Ä¤Q¨µ°jªk°|­­ÁY¸T¨î¥Oªº½d³ò¡A¦ýºû«ù½ßÀvªºª÷ÃB¡A»{¬°¬ü°ê°Ó¼Ðªkªº®Ä¤O¤Î©ó©Ò¦³Abitronªº¹Ò¥~«IÅv¦æ¬°[5]¡C

Abitron¤W¶D¨ì³Ì°ªªk°|¡A³Ì°ªªk°|©ó2003¦~6¤ë29¤é§@¥X§P¨M¡A±À½¤@¡B¤G¼f§P¨M¡CAlito¤jªk©x¼¶¼gªº¦h¼Æ·N¨£»{¬°¡A¬ü°ê°Ó¼Ðªkªº·l®`½ßÀv½d³ò¥u¤Î©ó¡u°ê¤º°Ó·~¤Wªº«IÅv¨Ï¥Î¡v¡]infringing use in commerce is domestic¡^[6]¡C

²Ä¤Q¨µ°jªk°|§P¨M¼Ú¬w«IÅv§P½ß¬ü°ê­ì§i9600¸U¬ü¤¸

Alito¤jªk©x«ü¥X¡A¡uµL¹Ò¥~®Ä¤O¤§±À©w¡v¬O¤@­Óªø´Á¥H¨Óªº­ì«h¡C¤W­z±À©w¦³¤G­Ó¨BÆJ¡C

¤@¡B¸Óªk³W¥»¨­¬O§_ª½±µºÞ¨ì¹Ò¥~¨Æ¶µ¡C¥ç§Y¡A¬ü°ê°ê·|¬O§_©ú½TµL»~¦a«ü¥Ü¡A¸Óªk±øÀ³¾A¥Î¦b¹Ò¥~¦æ¬°¡C¦pªG¬ü°ê°ê·|´£¨Ñ¤F¦¹ºØ«ü¥Ü¡A¨º»ò¸Óªk±ø´N¦³¹Ò¥~®Ä¤O¡C

¤G¡B¦pªG¨S¦³¸Ó«ü¥Ü¡A«h­n¶i¤J²Ä¤G¨BÆJ¡C¥ç§Y¡A­Ó®×ªº¾A¥Î¤W¡A¬O§_±N¹Ò¥~¦æ¬°·í¦¨¬O¸Ó±ø¤åªº°ê¤º¾A¥Î¡]domestic application¡^¡CÃöÁä¦b©ó¡A½T»{¬ÛÃö±ø¤å­I«á°ê·|Ãöª`ªº¡uµJÂI¡v¡A¥B§PÂ_¡u»P¸ÓµJÂI¬ÛÃöªº¦æ¬°¬O§_µo¥Í¦b¬ü°ê¹Ò¤º¡v[7]¡C

Alito¤jªk©x±j½Õ¡A¨Ã«D§ä¨ì¡uµJÂI¡v´N¦n¡A¤§«eªº§P¨M¥ý¨Ò±j½Õ¡A­n±´¨s¡u»P¸ÓµJÂI¬ÛÃöªº¦æ¬°¬O§_µo¥Í¦b¬ü°ê¹Ò¤º¡v[8]¡C¦]¦¹¡A­nÃÒ©ú©Ò½Ð¨D¯A¤Î¡u±ø¤åªº°ê¤º¾A¥Î¡v¡A­ì§i¥²¶·ÃÒ©ú¡A»P¸Ó±ø¤åµJÂI¦³Ãöªº¦æ¬°¤Dµo¥Í¦b¬ü°ê¹Ò¤º¡C

¬ü°ê°Ó¼Ðªk²Ä1114±ø(1)(a)©Î1125±ø(a)(1)¨S¦³©ú½T«ü¥Ü¥i¾A¥Î¹Ò¥~

Alito¤jªk©x«ü¥X¡A¬ü°ê°Ó¼Ðªk²Ä1114±ø(1)(a)©Î1125±ø(a)(1) ¡A³£¥u´£¨ì¸T¤î¥i¯à·|³y¦¨²V²c»~»{ªº¡u°Ó·~¤W¨Ï¥Î¡v¡A¨S¦³©ú½T³W©w¹Ò¥~¾A¥Î¡A¤]¨S¦³¥ô¦ó¨ä¥L²M·¡¸ñ¶HÅã¥Ü¡A¨äÄÝ©ó¥i¾A¥Î©ó¹Ò¥~ªº¡u¨u¨£±ø´Ú¡v¡C

¦]¦Ó¡A¥²¶·¶i¤J²Ä¤G¨BÆJªº§PÂ_¡A¥ç§Y¡A½Ð¨D½ßÀv¬O§_ÄÝ©ó¸Ó±ø¤åªº¡u°ê¤º¾A¥Î¡v¡HAlito¤jªk©x»{¬°¡A¾A·íªº¼Ð·ÇÀ³¸Ó¬OÃöª`¡u»P¸Ó±ø¤åµJÂI¦³Ãö¦æ¬°ªº¦aÂI¡v¡]location of the conduct relevant to the focus¡^¡C ¦ý¥»®×Âù¤èªºÅG½×¥uÃö¤ß¸Ó±ø¤åªº¡uµJÂI¡v¡A¦Ó¨S°Q½×¡u»PµJÂI¦³Ãöªº¦æ¬°¡v¡C

¨tª§±ø¤å¾A¥ÎªºµJÂI¬O¡u°Ó·~¤Wªº«IÅv¨Ï¥Î¡v

Alito¤jªk©x±j½Õ¡A¤@±ø¤å¡u¤¹³\ªº°ê¤º¾A¥Î¡vÀ³¸Ó¬OÃö¤ß¡u¸Ó»P¸ÓµJÂI¦³Ãöªº¦æ¬°ªº¦aÂI¡v¡C¦Ó¨tª§±ø¤å¤¤¡u»PµJÂI¦³Ãöªº¦æ¬°¡vÀ³¸Ó¬O¡u°Ó·~¤Wªº«IÅv¨Ï¥Î¡v¡C

¡i¥»¤å¥¼§¹¡A§¹¾ã¤º®e½Ð¨£¡m¥_¬ü´¼Åv³ø¡n337´Á¡G¬ü°ê³Ì°ªªk°|¬°°Ó¼Ð«IÅv¹Ò¥~®Ä¤O¹º¬É½u¡G2023¦~Abitron Austria GmbH v. Hetronic Int'l, Inc.®×¡j

¡°¦p±ýÂà¸ü¥»¤å¡A½Ð»P¥_¬ü´¼Åv³øÁpµ¸

 
 
¥»¹q¤l³øµÛ§@Åv§¡ÄÝ¡uÁp¦X½u¤W¤½¥q¡v©Î±ÂÅv¡uÁp¦X½u¤W¤½¥q¡v¨Ï¥Î¤§¦XªkÅv§Q¤H©Ò¦³¡A
¸T¤î¥¼¸g±ÂÅvÂà¸ü©Î¸`¿ý¡C­Y¹ï¹q¤l³ø¤º®e¦³¥ô¦óºÃ°Ý©Î­n¨DÂà¸ü±ÂÅv¡A½Ð¡i
Ápµ¸§Ú­Ì¡j¡C
  §K¶O¹q¤l³ø | µÛ§@ÅvÁn©ú | Áô¨pÅvÁn©ú | Ápµ¸§Ú­Ì